April 30 (Reuters) - Eli Lilly ( LLY ) beat Wall Street

estimates for first-quarter profit on Tuesday, helped by rising

demand for its weight-loss treatment Zepbound and type 2

diabetes drug Mounjaro.

The Indianapolis-based drugmaker posted a profit of $2.58

per share on an adjusted basis, compared with analysts'

expectations of $2.46 per share, according to LSEG data.

(Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru and

Patrick Wingrove in New York; Editing by Devika Syamnath)